{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T03:32:39Z","timestamp":1763436759342,"version":"build-2065373602"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.critrevonc.2022.103698","type":"journal-article","created":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T11:55:47Z","timestamp":1651665347000},"page":"103698","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["The application of cancer stem cell model in malignant mesothelioma"],"prefix":"10.1016","volume":"174","author":[{"given":"Giuseppe","family":"Bronte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio Domenico","family":"Procopio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Graciotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"77","key":"10.1016\/j.critrevonc.2022.103698_bib1","doi-asserted-by":"crossref","first-page":"34495","DOI":"10.18632\/oncotarget.26130","article-title":"Transglutaminase is a mesothelioma cancer stem cell survival protein that is required for tumor formation","volume":"9","author":"Adhikary","year":"2018","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103698_bib2","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1073\/pnas.0530291100","article-title":"Prospective identification of tumorigenic breast cancer cells","volume":"100","author":"Al-Hajj","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"10272","key":"10.1016\/j.critrevonc.2022.103698_bib3","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103698_bib4","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S1470-2045(13)70257-2","article-title":"Asbestos is not just asbestos: an unrecognised health hazard","volume":"14","author":"Baumann","year":"2013","journal-title":"Lancet Oncol."},{"issue":"5\u20136","key":"10.1016\/j.critrevonc.2022.103698_bib5","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/10937404.2016.1195322","article-title":"Environmental risk of mesothelioma in the United States: an emerging concern-epidemiological issues","volume":"19","author":"Baumann","year":"2016","journal-title":"J. Toxicol. Environ. Health B Crit. Rev."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103698_bib6","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.stemcr.2017.02.005","article-title":"Stem cell factor-based identification and functional properties of in vitro-selected subpopulations of malignant mesothelioma cells","volume":"8","author":"Blum","year":"2017","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.critrevonc.2022.103698_bib7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.critrevonc.2016.08.011","article-title":"The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?","volume":"107","author":"Bronte","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103698_bib8","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat. Genet."},{"issue":"26","key":"10.1016\/j.critrevonc.2022.103698_bib9","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1038\/onc.2011.485","article-title":"SASP mediates chemoresistance and tumor-initiating-activity of mesothelioma cells","volume":"31","author":"Canino","year":"2012","journal-title":"Oncogene"},{"issue":"33","key":"10.1016\/j.critrevonc.2022.103698_bib10","doi-asserted-by":"crossref","first-page":"13618","DOI":"10.1073\/pnas.1105887108","article-title":"Erionite exposure in North Dakota and Turkish villages with mesothelioma","volume":"108","author":"Carbone","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103698_bib11","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/1078-0432.CCR-11-2259","article-title":"Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma","volume":"18","author":"Carbone","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2022.103698_bib12","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.21037\/tlcr.2020.02.03","article-title":"SV40 and human mesothelioma","volume":"9","author":"Carbone","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.critrevonc.2022.103698_bib13","first-page":"5664","article-title":"Mesothelioma Malignancy and the Microenvironment: Molecular Mechanisms","volume":"13","author":"Cersosimo","year":"2021"},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103698_bib14","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.cell.2013.06.005","article-title":"Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity","volume":"154","author":"Chaffer","year":"2013","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103698_bib15","doi-asserted-by":"crossref","first-page":"270","DOI":"10.21037\/tlcr.2017.05.03","article-title":"BAP1, a tumor suppressor gene driving malignant mesothelioma","volume":"6","author":"Cheung","year":"2017","journal-title":"Transl. Lung Cancer Res."},{"issue":"19","key":"10.1016\/j.critrevonc.2022.103698_bib16","doi-asserted-by":"crossref","first-page":"9339","DOI":"10.1158\/0008-5472.CAN-06-3126","article-title":"Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells","volume":"66","author":"Clarke","year":"2006","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103698_bib17","first-page":"437","article-title":"Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed","volume":"37","author":"Cortes-Dericks","year":"2010","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103698_bib18","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/1471-2407-14-304","article-title":"Cisplatin-resistant cells in malignant pleural mesothelioma cell lines show ALDH(high)CD44(+) phenotype and sphere-forming capacity","volume":"14","author":"Cortes-Dericks","year":"2014","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103698_bib19","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.stem.2010.05.021","article-title":"Primary tumor genotype is an important determinant in identification of lung cancer propagating cells","volume":"7","author":"Curtis","year":"2010","journal-title":"Cell Stem Cell"},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103698_bib20","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/ijc.29391","article-title":"Inhibition of mesothelioma cancer stem-like cells with adenovirus-mediated NK4 gene therapy","volume":"137","author":"Deng","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2022.103698_bib21","unstructured":"FDA: U.S. Food and Drug Administration. FDA Approves Drug Combination For Treating Mesothelioma. Press release. Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-drug-combination-treating-mesothelioma (accessed on 17th January 2022)."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103698_bib22","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.bbrc.2010.12.054","article-title":"Identification of cancer stem cell markers in human malignant mesothelioma cells","volume":"404","author":"Ghani","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103698_bib23","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103698_bib24","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.lungcan.2010.04.020","article-title":"Characterization of side population cells in human malignant mesothelioma cell lines","volume":"70","author":"Kai","year":"2010","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103698_bib25","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1158\/1541-7786.MCR-19-0914","article-title":"The YAP1 signaling inhibitors, verteporfin and CA3, suppress the mesothelioma cancer stem cell phenotype","volume":"18","author":"Kandasamy","year":"2020","journal-title":"Mol. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103698_bib26","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1158\/1078-0432.CCR-11-0962","article-title":"Polycomb repressor complex-2 is a novel target for mesothelioma therapy","volume":"18","author":"Kemp","year":"2012","journal-title":"Clin Cancer Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103698_bib27","doi-asserted-by":"crossref","first-page":"285","DOI":"10.5483\/BMBRep.2017.50.6.039","article-title":"Cancer stem cell surface markers on normal stem cells","volume":"50","author":"Kim","year":"2017","journal-title":"BMB Rep."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103698_bib28","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S1470-2045(22)00061-4","article-title":"Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial","volume":"23","author":"Kindler","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2022.103698_bib29","first-page":"2186","article-title":"Meta-Analysis of Survival and Development of a Prognostic Nomogram for Malignant Pleural Mesothelioma Treated with Systemic Chemotherapy","volume":"13","author":"Kotecha","year":"2021"},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103698_bib30","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.stem.2014.02.006","article-title":"Evolution of the cancer stem cell model","volume":"14","author":"Kreso","year":"2014","journal-title":"Cell Stem Cell"},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2022.103698_bib31","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/j.lungcan.2005.03.017","article-title":"Implications of P16\/CDKN2A deletion in pleural mesotheliomas","volume":"49","author":"Ladanyi","year":"2005","journal-title":"Lung Cancer"},{"issue":"6464","key":"10.1016\/j.critrevonc.2022.103698_bib32","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/367645a0","article-title":"A cell initiating human acute myeloid leukaemia after transplantation into SCID mice","volume":"367","author":"Lapidot","year":"1994","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103698_bib33","first-page":"2153","article-title":"SDF1\/CXCL12 is involved in recruitment of stem-like progenitor cells to orthotopic murine malignant mesothelioma spheroids","volume":"30","author":"Lau","year":"2010","journal-title":"Anticancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103698_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100446","article-title":"Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17\/16 study","volume":"7","author":"Mark","year":"2022","journal-title":"ESMO Open"},{"issue":"7467","key":"10.1016\/j.critrevonc.2022.103698_bib35","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nature12624","article-title":"Tumour heterogeneity and cancer cell plasticity","volume":"501","author":"Meacham","year":"2013","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103698_bib36","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1158\/0008-5472.CAN-13-2062","article-title":"Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis","volume":"74","author":"Menges","year":"2014","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103698_bib37","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.stem.2011.02.020","article-title":"The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse","volume":"8","author":"Merlos-Su\u00e1rez","year":"2011","journal-title":"Cell Stem Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103698_bib38","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/ijc.32419","article-title":"Wnt\/IL-1\u03b2\/IL-8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5","volume":"146","author":"Milosevic","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2022.103698_bib39","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1476-069X-7-4","article-title":"Translocation pathways for inhaled asbestos fibers","volume":"7","author":"Miserocchi","year":"2008","journal-title":"Environ. Health"},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103698_bib40","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrc3184","article-title":"Cancer stem cells: an evolving concept","volume":"12","author":"Nguyen","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"48","key":"10.1016\/j.critrevonc.2022.103698_bib41","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2111946118","article-title":"BAP1 forms a trimer with HMGB1 and HDAC1 that modulates gene \u00d7 environment interaction with asbestos","volume":"118","author":"Novelli","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"49","key":"10.1016\/j.critrevonc.2022.103698_bib42","doi-asserted-by":"crossref","first-page":"6357","DOI":"10.1038\/s41388-018-0405-y","article-title":"Differential regulation of the sphere formation and maintenance of cancer-initiating cells of malignant mesothelioma via CD44 and ALK4 signaling pathways","volume":"37","author":"Ohno","year":"2018","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103698_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0119549","article-title":"Characterisation of mesothelioma-initiating cells and their susceptibility to anti-cancer agents","volume":"10","author":"Pasdar","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103698_bib44","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/onc.2015.125","article-title":"Role of Merlin\/NF2 inactivation in tumor biology","volume":"35","author":"Petrilli","year":"2016","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103698_bib45","first-page":"1996","article-title":"Tumors as caricatures of the process of tissue renewal: prospects for therapy by directing differentiation","volume":"48","author":"Pierce","year":"1988","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2022.103698_bib46","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Mortality - All COD, Aggregated With State, Total U.S. (1969\u20132019) <Katrina\/Rita Population Adjustment>, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2021. Underlying mortality data provided by NCHS (www.cdc.gov\/nchs)."},{"key":"10.1016\/j.critrevonc.2022.103698_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103639","article-title":"A systematic review and meta-analysis of trials assessing PD-1\/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma","volume":"172","author":"Tagliamento","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103698_bib48","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat. Genet."},{"key":"10.1016\/j.critrevonc.2022.103698_bib49","doi-asserted-by":"crossref","DOI":"10.1136\/thoraxjnl-2021-217709","article-title":"Incidence, treatment and survival of malignant pleural and peritoneal mesothelioma: a population-based study","author":"van Kooten","year":"2022","journal-title":"Thorax"},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103698_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052825","article-title":"Multipotent cancer stem cells derived from human malignant peritoneal mesothelioma promote tumorigenesis","volume":"7","author":"Varghese","year":"2012","journal-title":"PLoS One"},{"issue":"14","key":"10.1016\/j.critrevonc.2022.103698_bib51","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103698_bib52","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1186\/s12885-018-4354-1","article-title":"Putative cancer stem cells may be the key target to inhibit cancer cell repopulation between the intervals of chemoradiation in murine mesothelioma","volume":"18","author":"Wu","year":"2018","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103698_bib53","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.bbrc.2012.02.054","article-title":"Characterization of cancer stem cell properties of CD24 and CD26-positive human malignant mesothelioma cells","volume":"419","author":"Yamazaki","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842822001226?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842822001226?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:43:56Z","timestamp":1760903036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842822001226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":53,"alternative-id":["S1040842822001226"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103698","relation":{},"ISSN":["1040-8428"],"issn-type":[{"type":"print","value":"1040-8428"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The application of cancer stem cell model in malignant mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103698","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103698"}}